Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SPX 101 - Sparx Therapeutics/Tillead Therapeutics

Next Previous
Drug Profile

SPX 101 - Sparx Therapeutics/Tillead Therapeutics

Alternative Names: Anti-claudin 18.2 antibody - Sparx Therapeutics/Tillead Therapeutics; Anti-CLDN 18.2 antibody - Sparx Therapeutics/Tillead Therapeutics; SPX-101 - Sparx Therapeutics/Tillead Therapeutics

Latest Information Update: 15 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sparx Therapeutics; Tillead Therapeutics
  • Developer Sparx Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 31 Oct 2024 SparX Biotech withdraws a phase I trial in Solid tumours (Second line therapy or greater, metastatic disease, Late-stage disease, Inoperable/unresectable, Recurrent) due to re-prioritised development strategy (NCT05231733)
  • 31 Oct 2023 Phase-I clinical trials in Cancer in USA (Parenteral), prior to October 2023 (Sparx Therapeutics pipeline, October 2023)
  • 17 Jan 2022 Sparx Therapeutics plans a clinical trial for Cancers in USA in March 2022 (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top